Form 8-K - Current report:
SEC Accession No. 0001193125-21-320242
Filing Date
2021-11-04
Accepted
2021-11-04 16:44:28
Documents
14
Period of Report
2021-11-02
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d599039d8k.htm   iXBRL 8-K 30802
2 EX-1.1 d599039dex11.htm EX-1.1 324443
3 EX-99.1 d599039dex991.htm EX-99.1 15575
  Complete submission text file 0001193125-21-320242.txt   562518

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA teva-20211102.xsd EX-101.SCH 2895
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20211102_lab.xml EX-101.LAB 17306
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20211102_pre.xml EX-101.PRE 10931
7 EXTRACTED XBRL INSTANCE DOCUMENT d599039d8k_htm.xml XML 3422
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 211380596
SIC: 2834 Pharmaceutical Preparations